X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants
X4 Pharmaceuticals, Inc. (XFOR)
Last x4 pharmaceuticals, inc. earnings: 3/12 07:30 am
Check Earnings Report
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 3,666,667 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 1,750,000 shares of common stock, and accompanying Class B warrants to purchase 5,416,667 shares of its common stock (or, for investors who so choose, pre-funded warrants to purchase shares of common stock) at a price to the public of $12.00 per share and accompanying Class B warrant (or $11.999 per pre-funded warrant and accompanying Class B warrant). X4’s gross proceeds from this offering are expected to be approximately $65.0 million, before deducting underwriting discounts and estimated offering expenses. All of the securities in the offering are being sold by X
Show less
Read more
Impact Snapshot
Event Time:
XFOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XFOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XFOR alerts
High impacting X4 Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
XFOR
News
- X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition [Yahoo! Finance]Yahoo! Finance
- X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & ExpositionGlobeNewswire
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare ConferenceGlobeNewswire
- Biopharma Leaders of Color (BLOC) Announces Board of Directors and Establishes Executive Council to Expand and Enhance Offerings [Yahoo! Finance]Yahoo! Finance
XFOR
Earnings
- 11/13/24 - Miss
XFOR
Analyst Actions
- 11/14/24 - Stifel
XFOR
Sec Filings
- 11/19/24 - Form 4
- 11/15/24 - Form 144
- 11/13/24 - Form 10-Q
- XFOR's page on the SEC website